Loading...
XNASNVCR
Market cap3.33bUSD
Dec 20, Last price  
30.80USD
1D
1.32%
1Q
76.50%
Jan 2017
292.36%
IPO
64.79%
Name

Novocure Ltd

Chart & Performance

D1W1MN
XNAS:NVCR chart
P/E
—
P/S
6.54
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
2.99%
Rev. gr., 5y
15.47%
Revenues
509m
-5.30%
10,359,00015,490,00033,087,00082,888,000177,026,000248,069,000351,318,000494,366,000535,031,000537,840,000509,338,000
Net income
-207m
L+123.75%
-77,370,000-80,682,000-111,581,000-131,845,000-61,662,000-63,559,000-7,230,00019,808,000-58,351,000-92,534,000-207,043,000
CFO
-73m
L
-52,717,000-74,244,000-99,884,000-107,592,000-33,134,000-1,865,00026,620,00099,148,00082,756,00030,788,000-73,336,000
Earnings
Jun 05, 2025

Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
URL
https://www.novocure.com/
IPO date
Oct 01, 2015
Employees
1,320
Domiciled in
JE
Incorporated in
JE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
509,338
-5.30%
537,840
0.53%
535,031
8.23%
Cost of revenue
742,208
627,363
579,364
Unusual Expense (Income)
NOPBT
(232,870)
(89,523)
(44,333)
NOPBT Margin
Operating Taxes
15,303
10,688
6,276
Tax Rate
NOPAT
(248,173)
(100,211)
(50,609)
Net income
(207,043)
123.75%
(92,534)
58.58%
(58,351)
-394.58%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,416
5,224
4,546
BB yield
-0.28%
-0.07%
-0.06%
Debt
Debt current
73,580
70,002
Long-term debt
623,662
603,033
588,210
Deferred revenue
2,878
6,477
Other long-term liabilities
8,276
4,552
166
Net debt
(286,954)
(292,812)
(279,488)
Cash flow
Cash from operating activities
(73,336)
30,788
82,756
CAPEX
(27,093)
(21,358)
(24,170)
Cash from investing activities
184,148
(139,957)
(144,834)
Cash from financing activities
15,787
15,491
25,702
FCF
(213,811)
(115,162)
(76,348)
Balance
Cash
910,616
969,425
937,700
Long term investments
Excess cash
885,149
942,533
910,948
Stockholders' equity
(990,972)
(780,893)
(689,095)
Invested Capital
1,957,986
1,878,684
1,745,650
ROIC
ROCE
EV
Common stock shares outstanding
106,391
104,660
103,433
Price
14.93
-79.65%
73.35
-2.30%
75.08
-56.61%
Market cap
1,588,420
-79.31%
7,676,846
-1.15%
7,765,770
-58.78%
EV
1,301,466
7,384,034
7,486,282
EBITDA
(221,901)
(78,899)
(34,082)
EV/EBITDA
Interest
3,319
3,334
3,440
Interest/NOPBT